- Home Page
- Sales & Partners
- News & Events
- Site Map
|Method & Line||Sample & Target||Product||Package Info||Product||Package Info|
|MicroELISA||Plasma,Serum||EIAgen Anti-CORE IgM Kit||Tests per Package: 96|
|EIAgen||Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination of IgM class antibodies to Hepatitis B Virus core Antigen in human plasma and sera with the "capture" system. The kit is intended for the classification of the viral agent and for the follow-up of chronic patients under therapy.||Code: 071003||Package: 1 Microplate|
Please pay attention to the revision of the document that must be the same as the revision reported in the box label.
In case of discrepancy please contact our Customer Care e-mail: email@example.com.
* Other document related to the product available at Documentation Centre and it is accessible for Adaltis distributors/partners after registration only.
Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination of IgM class antibodies to Hepatitis B Virus core Antigen in human plasma and sera with the "capture" system. The kit is intended for the classification of the viral agent and for the follow-up of chronic patients under therapy. For “in vitro” diagnostic use only.
Hepatitis B core Antigen (or HBcAg) is the major component of the core particles of Hepatitis B virus (or HBV). Particles have a size of 27nm and contain a circular doublestranded DNA molecule, a specific DNA-polymerase and HBeAg, HBcAg is composed of a single polypeptide of about 17 kD that is released upon disaggregation of the core particles; the antigen contains at least one immunological determinant.
Upon primary infection, anti HBcAg IgM antibodies are one of the first markers of HBV hepatitis appearing in the serum of the patient, together or slightly later than HBsAg, the viral surface antigen.
Anti HBcAg IgM titers, very high during the acute phase, decrease along the illness, as IgG antibodies appear, down to undetectable levels in convalescent patients.
In chronic hepatitis, however, spikes of anti HBcAg IgM synthesis are present, confirming reactivation of HBV in hepatocites and giving origin to permanent IgM low titers. The determination of anti HBcAg IgM antibodies has become very important for the fast classification of the virus, of the phase of the illness and for the monitoring of patients under treatment with interferon.
The assay is based on the principle of "IgM capture" where IgM class antibodies in the sample are first captured by the solid phase coated with anti hIgM antibody. After washing out all the other components of the sample and in particular IgG antibodies, the specific IgM captured on the solid phase are detected by the addition of a purified preparation of recombinant HBcAg, labelled with a monoclonal antibody conjugated with peroxidase (HRP).
After incubation, microwells are washed to remove unbound conjugate and then the substrate TMB is added. In the presence of peroxidase the colourless substrate is hydrolysed to a coloured end-product, whose optical density may be detected and is proportional to the amount of IgM antibodies to HBcAg present in the sample.
Each kit contains sufficient reagents to perform 96 tests (code 071003).
Wash Buffer Concentrate 20x
Plate seal foils
Number of tests